The Burbank, California-based non-profit phaware is a global association dedicated to creating awareness about pulmonary hypertension through engagement and technological innovation to discover and chart the course to a cure. Pulmonary hypertension (PH) is a rare, chronic lung disease that affects the functioning of the heart and can lead to fatal…
News
Complexa Inc., a biopharmaceutical company developing therapies to treat fibrosis and inflammation-related diseases, announced the successful completion of a Phase 1 clinical program of its lead drug candidate CXA-10, and the beginning of preparations for Phase 2 clinical trials for focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH) in 2016. The announcement builds…
Boehringer Ingelheim Pharmaceuticals, Inc. and the Pulmonary Fibrosis Foundation (PFF) have announced a five-year partnership in an effort to raise awareness for the disease and provide patients with disease education. Boehringer Ingelheim’s investment will also contribute to research funding of early diagnosis techniques and new therapies. Pulmonary Fibrosis (PF),…
The California Chapter of the Pulmonary Hypertension Association will host its Second Annual Long Beach O2 breathe Walk in Long Beach, California, on Saturday, Nov. 14, at 9 a.m. PT at El Dorado Regional Park. The event, dubbed the O2 breathe Walk, is a fundraising campaign that gathers together families, friends…
Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company that develops and commercializes drugs for the treatment of orphan diseases and conditions with ineffective current treatments, announced a new license agreement with a leading Japanese pharmaceutical company, Nippon Kayaku. Eiger BioPharmaceuticals aims to develop Nippon Kayaku’s therapeutic drug Bestatin™ (ubenimex) for the treatment of pulmonary…
A new study by Romanian and Belgian scientists sheds light on specific conditions associated with pulmonary hypertension (PH), and which of those conditions are associated with a better prognosis for survival. The report, titled “Is Right Ventricular Remodeling in Pulmonary Hypertension Dependent on Etiology? An Echocardiographic Study,”appeared in the…
The American Heart Association (AHA) and American Thoracic Society (ATS) have issued new guidelines pertaining to Pediatric Pulmonary Hypertension. The revisions come as a result of collaboration between the agencies and were developed in a joint effort by an interdisciplinary team of 27 experienced clinicians and clinician-scientists in a review…
Recently published research reveals that orthopedic (musculoskeletal) surgery in patients with pulmonary hypertension (PH), while challenging, is feasible and offers decent outcomes even in severe stages of the disease, provided proper care is given. The paper entitled “Perioperative management of patients with severe pulmonary hypertension in major orthopedic surgery: experience-based recommendations“ was published in…
Right ventricular (RV) dysfunction is a characteristic of several disorders such as pulmonary hypertension, congenital heart disease and cardiomyopathy, making RV function evaluation key to effective prognosis and diagnostic value in such disorders. However, diagnosis through RV function is challenging due to anatomical configuration of the RV. Right ventricular outflow tract (RVOT)…
In a new study entitled “Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: The PHACeT Trial,” researchers performed the first human trial to investigate the therapeutic potential of endothelial progenitor cells in repairing the damaged vessels in pulmonary arterial hypertension patients who have failed to…
Dublin, Ireland, based biopharmaceutical company Mallinckrodt plc reports that its INOmax (nitric oxide) vasodilator inhalation device has received regulatory approval in Australia and Japan for treating pulmonary hypertension in conjunction with heart surgery. The Australian Therapeutic Goods Administration (TGA) has approved INOmax for peri- and post-operative pulmonary hypertension…
November is Pulmonary Hypertension Awareness Month and the Pulmonary Hypertension Association (PHA) is planning to launch a new public service campaign called Heart2CurePH that promises to increase understanding of pulmonary hypertension (PH). The worldwide educational campaign will include TV, radio, and place-based and print materials, while anyone on social media can…
